Cytosorbents Corp (NASDAQ:CTSO) has been given an average rating of “Buy” by the six brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $12.81.

A number of research firms have issued reports on CTSO. Maxim Group set a $10.00 target price on Cytosorbents and gave the stock a “buy” rating in a research report on Thursday, December 20th. BidaskClub upgraded Cytosorbents from a “strong sell” rating to a “sell” rating in a research report on Tuesday, November 27th. Finally, HC Wainwright set a $15.00 price target on Cytosorbents and gave the company a “buy” rating in a research report on Wednesday, November 7th.

NASDAQ:CTSO opened at $8.02 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 7.03 and a quick ratio of 6.85. Cytosorbents has a 1 year low of $6.60 and a 1 year high of $14.95. The firm has a market capitalization of $254.80 million, a price-to-earnings ratio of -25.06 and a beta of 0.92.

Cytosorbents (NASDAQ:CTSO) last released its earnings results on Wednesday, November 7th. The medical research company reported ($0.10) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.04. Cytosorbents had a negative return on equity of 90.18% and a negative net margin of 70.97%. The business had revenue of $5.74 million during the quarter, compared to the consensus estimate of $5.79 million. On average, equities research analysts predict that Cytosorbents will post -0.51 EPS for the current fiscal year.

In other news, insider Phillip P. Chan sold 24,337 shares of Cytosorbents stock in a transaction on Friday, December 7th. The stock was sold at an average price of $9.37, for a total value of $228,037.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.90% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Teachers Advisors LLC boosted its stake in Cytosorbents by 11.1% during the third quarter. Teachers Advisors LLC now owns 60,875 shares of the medical research company’s stock valued at $785,000 after buying an additional 6,069 shares during the period. MetLife Investment Advisors LLC boosted its stake in Cytosorbents by 55.2% during the third quarter. MetLife Investment Advisors LLC now owns 22,940 shares of the medical research company’s stock valued at $296,000 after buying an additional 8,155 shares during the period. Manatuck Hill Partners LLC boosted its stake in Cytosorbents by 17.5% during the third quarter. Manatuck Hill Partners LLC now owns 303,300 shares of the medical research company’s stock valued at $3,913,000 after buying an additional 45,100 shares during the period. Allianz Asset Management GmbH boosted its stake in Cytosorbents by 35.9% during the third quarter. Allianz Asset Management GmbH now owns 350,178 shares of the medical research company’s stock valued at $4,517,000 after buying an additional 92,508 shares during the period. Finally, United Services Automobile Association bought a new stake in Cytosorbents during the third quarter valued at $2,472,000. Institutional investors own 25.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.

Read More: Outstanding Shares

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.